Streetbeat News

Earnings

PHIN

PHINIA forecasts FY24 sales to be between $3.42B-$3.57B with adjusted sales in the range of $3.40B-$3.55B. The company also anticipates generating $160M-$200M in adjusted free cash flow.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:59 pm

RIO

Rio Tinto PLC (NYSE:RIO) shares fell in premarket trading after reporting a 3% decline in sales revenue to $54.0 billion for FY23, slightly beating consensus but with a 12% decrease in underlying EPS to $7.25, missing expectations. Production increased in Pilbara iron ore and aluminium, but underlying EBITDA and operating cash flow declined due to lower aluminium pricing. The company announced a major renewable power purchase agreement in Australia and expects a production uplift and significant capital investment in the coming years.

Portfolio Pulse from Lekha Gupta

February 21, 2024 | 12:52 pm

ALIT

Alight has provided its financial projections for FY24, expecting revenue to be in the range of $3.55B-$3.61B, which is below the market estimate of $3.71B. However, its projected adjusted EPS of $0.72-$0.77 is around the market estimate of $0.73.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:48 pm

AEHR

Aehr announced receiving $23M in new follow-on orders to address the increasing demand for wafer level test and burn-in of silicon carbide semiconductor devices. This development highlights the company's growing role in the semiconductor industry and its ability to meet rising market demands.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:43 pm

ALIT

Alight (NYSE:ALIT) reported Q4 adjusted EPS of $0.30, surpassing the $0.26 estimate, marking a 42.86% year-over-year increase. However, its Q4 sales of $960M fell short of the $1.03B estimate, a 1.91% increase from the previous year.

Portfolio Pulse from saritha@benzinga.com

February 21, 2024 | 12:42 pm

KHC

Kraft Heinz reiterates its 2024 financial outlook, expecting organic net sales growth of 0%-2%, adjusted operating income growth of 2%-4%, and adjusted EPS of $3.01-$3.07, aligning with a $3.03 estimate. The company anticipates positive price contributions and volume increases in the second half, with a modest expansion in adjusted gross profit margin. Challenges include a potential $45 million impact from foreign currency and debt refinancing.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:41 pm

THTX

Theratechnologies forecasts its fiscal year 2024 sales to be between $87M-$90M, which is below the consensus estimate of $92.85M. The company also expects adjusted EBITDA to be between $13M-$15M.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:38 pm

PHIN

Phinia reported a significant decrease in its Q4 adjusted EPS to $0.71 from $1.75 YoY, despite a slight increase in sales to $882.00M from $851.00M YoY.

Portfolio Pulse from mahesh@benzinga.com

February 21, 2024 | 12:37 pm

RGEN

Repligen forecasts its adjusted EPS for fiscal year 2024 to be between $1.42 and $1.49, which is below the consensus estimate of $1.77.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:36 pm

RGEN

Repligen projects its fiscal year 2024 revenue to be between $620M and $650M, which falls below the consensus estimate of $660.68M.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:36 pm